In silico identification and modification of T cell epitopes in pertussis antigens associated with tolerance

References

• Rumbo M, Hozbor D. Development of improved pertussis vaccine. Hum Vaccin Immunother. 2014;10:2450–53.
   PubMed Web of Science ®Google Scholar
• Halperin SA. The control of pertussis–2007 and beyond. N Engl J Med. 2007;356:110–13.
   PubMed Web of Science ®Google Scholar
• Libster R, Edwards KM. Re-emergence of pertussis: what are the solutions? Expert Rev Vaccines. 2012;11:1331–46.
   PubMed Web of Science ®Google Scholar
• Cagney M, MacIntyre CR, McIntyre P, Puech M, Giammanco A. The seroepidemiology of pertussis in Australia during an epidemic period. Epidemiol Infect. 2006;134:1208–16.
   PubMed Web of Science ®Google Scholar
• Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE, Group E-N. Resurgence of pertussis in Europe. Pediatr Infect Dis J. 2005;24:761–65.
   PubMed Web of Science ®Google Scholar
• Clark TA. Changing pertussis epidemiology: everything old is new again. J Infect Dis. 2014;209:978–81.
   PubMed Web of Science ®Google Scholar
• Fisman DN, Tang P, Hauck T, Richardson S, Drews SJ, Low DE, Jamieson F. Pertussis resurgence in Toronto, Canada: a population-based study including test-incidence feedback modeling. BMC Public Health. 2011;11:694.
   PubMed Web of Science ®Google Scholar
• Rodgers L, Martin SW, Cohn A, Budd J, Marcon M, Terranella A, Mandal S, Salamon D, Leber A, Tondella ML, et al. Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis–Ohio, 2010-2011. Clin Infect Dis. 2013;56:322–31.
   PubMed Web of Science ®Google Scholar
• McCarthy M. Acellular vaccines provided less protection during California pertussis outbreak. BMJ. 2013;346:f3325.
   PubMedGoogle Scholar
• Hozbor D, Mooi F, Flores D, Weltman G, Bottero D, Fossati S, Lara C, Gaillard ME, Pianciola L, Zurita E, et al. Pertussis epidemiology in Argentina: trends over 2004-2007. J Infect. 2009;59:225–31.
   PubMed Web of Science ®Google Scholar
• Cherry JD. Epidemic pertussis in 2012–the resurgence of a vaccine-preventable disease. N Engl J Med. 2012;367:785–87.
   PubMed Web of Science ®Google Scholar
• Sato Y, Kimura M, Fukumi H. Development of a pertussis component vaccine in Japan. Lancet. 1984;1:122–26.
   PubMed Web of Science ®Google Scholar
• WHO. Pertussis vaccines: WHO position paper, August 2015–recommendations. Vaccine 2016;34:1423–25.
   PubMed Web of Science ®Google Scholar
• Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, Ciofi Degli Atti ML, Giammanco A, Panei P, Blackwelder WC, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto pertosse working group. N Engl J Med. 1996;334:341–48.
   PubMed Web of Science ®Google Scholar
• Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc group for the study of pertussis vaccines. Lancet. 1997;350:1569–77.
   PubMed Web of Science ®Google Scholar
• Kapil P, Merkel TJ. Pertussis vaccines and protective immunity. Curr Opin Immunol. 2019;59:72–78.
   PubMed Web of Science ®Google Scholar
• de Greeff SC, Teunis P, de Melker HE, Mooi FR, Notermans DW, Elvers B, Schellekens JF. Two-component cluster analysis of a large serodiagnostic database for specificity of increases of IgG antibodies against pertussis toxin in paired serum samples and of absolute values in single serum samples. Clin Vaccine Immunol. 2012;19:1452–56.
   PubMedGoogle Scholar
• Locht C. Will we have new pertussis vaccines? Vaccine. 2018;36:5460–69.
   PubMed Web of Science ®Google Scholar
• Roberts R, Moreno G, Bottero D, Gaillard ME, Fingermann M, Graieb A, Rumbo M, Hozbor D. Outer membrane vesicles as acellular vaccine against pertussis. Vaccine. 2008;26:4639–46.
   PubMed Web of Science ®Google Scholar
• Gaillard ME, Bottero D, Errea A, Ormazabal M, Zurita ME, Moreno G, Rumbo M, Castuma C, Bartel E, Flores D, et al. Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes. Vaccine. 2014;32:931–37.
   PubMed Web of Science ®Google Scholar
• Raeven RH, Brummelman J, Pennings JL, van der Maas L, Tilstra W, Helm K, Van Riet E, Jiskoot W, Van Els CA, Han WG, et al. Bordetella pertussis outer membrane vesicle vaccine confers equal efficacy in mice with milder inflammatory responses compared to a whole-cell vaccine. Sci Rep. 2016;6:38240.
   PubMed Web of Science ®Google Scholar
• Geurtsen J, Dzieciatkowska M, Steeghs L, Hamstra HJ, Boleij J, Broen K, Akkerman G, El Hassan H, Li J, Richards JC, et al. Identification of a novel lipopolysaccharide core biosynthesis gene cluster in Bordetella pertussis, and influence of core structure and lipid A glucosamine substitution on endotoxic activity. Infect Immun. 2009;77:2602–11.
   PubMed Web of Science ®Google Scholar
• Geurtsen J, Steeghs L, Hamstra HJ, Ten Hove J, de Haan A, Kuipers B, Tommassen J, van der Ley P. Expression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates the endotoxic activity of Bordetella pertussis. Infect Immun. 2006;74:5574–85.
   PubMed Web of Science ®Google Scholar
• van de Waterbeemd B, Streefland M, van der Ley P, Zomer B, van Dijken H, Martens D, Wijffels R, Van der Pol L. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine. 2010;28:4810–16.
   PubMed Web of Science ®Google Scholar
• van der Ley P, van der Biezen J, Poolman JT. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine. 1995;13:401–07.
   PubMed Web of Science ®Google Scholar
• Salverda ML, Meinderts SM, Hamstra HJ, Wagemakers A, Hovius JW, van der Ark A, Stork M, van der Ley P. Surface display of a borrelial lipoprotein on meningococcal outer membrane vesicles. Vaccine. 2016;34:1025–33.
   PubMed Web of Science ®Google Scholar
• Rouppe van der Voort E, Schuller M, Holst J, de Vries P, van der Ley P, van den Dobbelsteen G, Poolman J. Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys. Vaccine. 2000;18:1334–43.
   PubMed Web of Science ®Google Scholar
• Vaughan K, Seymour E, Peters B, Sette A. Substantial gaps in knowledge of Bordetella pertussis antibody and T cell epitopes relevant for natural immunity and vaccine efficacy. Hum Immunol. 2014;75:440–51.
   PubMed Web of Science ®Google Scholar
• Raeven RH, van der Maas L, Tilstra W, Uittenbogaard JP, Bindels TH, Kuipers B, van der Ark A, Pennings JL, van Riet E, Jiskoot W, et al. Immunoproteomic profiling of bordetella pertussis outer membrane vesicle vaccine reveals broad and balanced humoral immunogenicity. J Proteome Res. 2015;14:2929–42.
   PubMed Web of Science ®Google Scholar
• Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F, Leng Q, Abdel Hady KM, VerBerkmoes NC, Sztein MB, Losikoff PT, Martin WD, et al. The two-faced T cell epitope: examining the host-microbe interface with JanusMatrix. Hum Vaccin Immunother. 2013;9:1577–86.
   PubMed Web of Science ®Google Scholar
• Cummings CA, Bootsma HJ, Relman DA, Miller JF. Species- and strain-specific control of a complex, flexible regulon by Bordetella BvgAS. J Bacteriol. 2006;188:1775–85.
   PubMed Web of Science ®Google Scholar
• Moise L, Gutierrez A, Kibria F, Martin R, Tassone R, Liu R, Terry F, Martin B, De Groot AS. iVAX: an integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines. Hum Vaccin Immunother. 2015;11:2312–21.
   PubMed Web of Science ®Google Scholar
• Southwood S, Sidney J, Kondo A, Del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol. 1998;160:3363–73.
   PubMed Web of Science ®Google Scholar
• Liu R, Moise L, Tassone R, Gutierrez AH, Terry FE, Sangare K, Ardito MT, Martin WD, De Groot AS. H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance. Hum Vaccin Immunother. 2015;11:2241–52.
   PubMed Web of Science ®Google Scholar
• Losikoff PT, Mishra S, Terry F, Gutierrez A, Ardito MT, Fast L, Nevola M, Martin WD, Bailey-Kellogg C, De Groot AS, et al. HCV epitope, homologous to multiple human protein sequences, induces a regulatory T cell response in infected patients. J Hepatol. 2015;62:48–55.
   PubMed Web of Science ®Google Scholar
• Wada Y, Nithichanon A, Nobusawa E, Moise L, Martin WD, Yamamoto N, Terahara K, Hagiwara H, Odagiri T, Tashiro M, et al. A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines. Sci Rep. 2017;7:1283.
   PubMed Web of Science ®Google Scholar
• Moise L, McMurry JA, Buus S, Frey S, Martin WD, De Groot AS. In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes. Vaccine. 2009;27:6471–79.
   PubMed Web of Science ®Google Scholar
• Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom GT, Baxter-Lowe LA. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med. 2006;203:961–71.
   PubMed Web of Science ®Google Scholar
• van de Waterbeemd B, Streefland M, Pennings J, van der Pol L, Beuvery C, Tramper J, Martens D. Gene-expression-based quality scores indicate optimal harvest point in Bordetella pertussis cultivation for vaccine production. Biotechnol Bioeng. 2009;103:900–08.
   PubMed Web of Science ®Google Scholar
• Michalska M, Schultze-Seemann S, Kuckuck I, Wolf P. In vitro evaluation of humanized/de-immunized anti-PSMA immunotoxins for the treatment of prostate cancer. Anticancer Res. 2018;38:61–69.
   PubMed Web of Science ®Google Scholar
• Cantor JR, Yoo TH, Dixit A, Iverson BL, Forsthuber TG, Georgiou G. Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift. Proc Natl Acad Sci U S A. 2011;108:1272–77.
   PubMed Web of Science ®Google Scholar
• King C, EN G, Mazor R, JL L, Pastan I, Pepper M, Baker D. Removing T-cell epitopes with computational protein design. Proc Natl Acad Sci U S A. 2014;111:8577–82.
   PubMed Web of Science ®Google Scholar
• Federizon J, Lin YP, Lovell JF. Antigen engineering approaches for Lyme disease vaccines. Bioconjug Chem. 2019;30:1259–72.
   PubMed Web of Science ®Google Scholar
• Moise LM, Biron B, Boyle CM, Kurt Yilmaz N, Jang H, Schiffer C, Ross T, Martin WD, De Groot AS. T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response. Hum Vaccin Immunother. 2018;14:2203–07.
   PubMed Web of Science ®Google Scholar
• Raeven RH, Brummelman J, Pennings JLA, van der Maas L, Helm K, Tilstra W, Van Der Ark A, Sloots A, Van Der Ley P, Van Eden W, et al. Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination. Mucosal Immunol. 2018;11:979–93.
   PubMed Web of Science ®Google Scholar
• Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24:S58–61.
   PubMedGoogle Scholar